share_log

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

SEC announcement ·  Apr 15 16:29
Summary by Moomoo AI
CRISPR Therapeutics AG officer and director Samarth Kulkarni is set to sell 19,582 common shares on April 15, 2024, with an aggregate market value of approximately $1.17 million. The shares to be sold were acquired on the same date through a stock option exercise, with the securities obtained directly from the issuer and paid for in cash. Over the past three months, Kulkarni has sold a total of 130,755 shares of CRISPR Therapeutics, generating gross proceeds of nearly $8.95 million.
CRISPR Therapeutics AG officer and director Samarth Kulkarni is set to sell 19,582 common shares on April 15, 2024, with an aggregate market value of approximately $1.17 million. The shares to be sold were acquired on the same date through a stock option exercise, with the securities obtained directly from the issuer and paid for in cash. Over the past three months, Kulkarni has sold a total of 130,755 shares of CRISPR Therapeutics, generating gross proceeds of nearly $8.95 million.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more